Fresenius Kabi Recalls a Lot of Its Arthritis Biosimilar Tyenne Over Glass Particles

Fresenius Kabi has issued a nationwide recall of one lot of Tyenne (tocilizumab-aazg) injection after finding glass particles in the vials.

Exactly what is affected

Announced in mid-August 2026, the recall covers Tyenne 400 mg/20 mL vials, lot 16UI07, with an expiration date of August 2028, down to the user level.

The affected product was distributed nationwide to wholesalers, distributors and direct customers between March 3 and March 25.

“User level” is the broadest recall depth, meaning the notification extends beyond distributors to the clinics, hospitals and pharmacies holding the product — appropriate for something that may already be in a treatment room.

What Tyenne is used for

Tyenne is a biosimilar of tocilizumab, an interleukin-6 blocker used in rheumatoid arthritis and other inflammatory conditions.

IL-6 is a central inflammatory signalling molecule, and blocking its receptor interrupts a pathway driving joint inflammation and destruction. The drug is used in patients whose disease is inadequately controlled by conventional therapy, and it is given by infusion in the 400 mg/20 mL presentation.

That the affected product is a biosimilar is incidental to the safety issue — a particulate contamination problem is a manufacturing failure, unrelated to whether the molecule is an originator or a copy.

Why glass particles in an infusion matter

According to the company, injecting a product containing glass particulates could cause local irritation, pain or swelling at the infusion site, as well as phlebitis — inflammation of the veins.

The route explains the risk profile. This product is infused into a vein rather than injected into muscle or under the skin, so particles enter the circulation directly.

Small quantities of small particles are generally trapped in the lung capillary bed without obvious consequence, which is why the listed risks are local rather than catastrophic. Larger particles or greater quantities carry more serious potential — vessel occlusion and inflammatory reactions — and repeated exposure in a chronic therapy compounds it.

Where glass in a vial comes from

An internal investigation identified the glass particles, and the likely sources are worth understanding because they recur across injectable recalls.

Delamination is the most common: glass containers exposed to certain formulations over time can shed thin flakes from the interior surface, a process influenced by the glass type, the drug’s pH and buffer, and storage conditions. It develops over months, so it appears after release testing has passed.

Mechanical damage during filling is the other route — vials chipping against equipment or each other on a high-speed line, depositing fragments before sealing.

Both are difficult to detect reliably. Automated inspection systems examine every vial, and small particles in a 20 mL container are close to the limit of what such systems distinguish from acceptable variation.

What patients and providers should do

Fresenius Kabi is notifying distributors and customers by letter and arranging returns. Anyone holding the affected lot should stop using it and follow the return instructions.

Questions go to Fresenius Kabi USA Quality Assurance at 1-866-716-2459, Monday to Friday, 8 a.m. to 5 p.m. Central.

Patients should not change their treatment independently. Interrupting an IL-6 blocker risks a disease flare, and the appropriate action is for the provider to source an unaffected lot rather than for the patient to stop.

Reading a single-lot recall

A recall confined to one lot is meaningfully different from a product-wide action. It indicates the company traced the problem to a specific production run rather than a systematic process failure, which is what lot-based manufacturing records are designed to enable.

It also means the remaining supply is unaffected, so patients on the drug can generally continue treatment with a different lot — a considerably better position than a shortage.

Why particulate recalls have become more common

Recalls for visible particles in injectables occur regularly enough to be a recognised category, and the trend reflects better detection as much as worse manufacturing.

Automated visual inspection systems have improved considerably. Machines now examine every unit at high speed with cameras and image analysis capable of identifying particles smaller than a human inspector would reliably catch, and regulatory expectations have risen alongside that capability.

The consequence is that problems previously going undetected are now found — sometimes during routine stability testing months after release, which is how delamination issues typically surface. A recall is then triggered for product already distributed.

That is the system working rather than failing. A recall means a defect was identified and traced to specific lots, which is what pharmaceutical quality systems exist to achieve. The alternative — the same defect present and undetected — would be considerably worse and entirely invisible.

This is a product-safety notice, not medical advice. If you use this medication, do not change your treatment on your own — contact your healthcare provider.